Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03070054 · ClinicalTrials.gov registry record · Early Phase 1
LIA in Hip Arthroscopy Patients
A Early Phase 1 study of Pain, sponsored by University of Utah.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT03070054 is a Early Phase 1 study of Pain that has completed, run by University of Utah. The registered enrollment target is 74 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03070054, a Early Phase 1 study of Pain, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigator's are conducting a randomized, blinded study to determine if the extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine can improve the postoperative pain management of hip arthroscopy patients. Participants will be randomly assigned to the LIA group or non-LIA group prior to surgery. Participants, anesthesiologists and PACU nurses will be blinded to group assignment, however the surgeon administering the LIA will be unblinded.
Conditions Studied
Interventions
- DRUG 20ml 0.25% bupivacaine-epinephrine
Study Locations (1)
Utah
- University of Utah Orthopaedic Center - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2016-06 |
| Est. Completion | 2020-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03070054
The ClinicalTrials.gov registry entry for NCT03070054 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (76% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 1 intervention - of which 20ml 0.25% bupivacaine-epinephrine is the first listed.
NCT03070054 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT03070054 about?
NCT03070054 is a clinical study titled "LIA in Hip Arthroscopy Patients". The investigator's are conducting a randomized, blinded study to determine if the extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine can improve the postoperative pain management of hip arthroscopy patients. Participants will be randomly assigned t...
What is the current status of trial NCT03070054?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 74 participants. The study started on 2016-06. Estimated completion is 2020-03.
What conditions does trial NCT03070054 study?
This clinical trial studies the following conditions: Pain.
What interventions are being tested in trial NCT03070054?
The interventions under investigation include: 20ml 0.25% bupivacaine-epinephrine (DRUG).
Who is sponsoring clinical trial NCT03070054?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03070054 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination
RECRUITING · Early Phase 1
-
The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults
RECRUITING · Early Phase 1
-
Effects of Dronabinol in Opioid Maintained Patients
RECRUITING · Early Phase 1
-
Remimazolam NeuroImaging
RECRUITING · Early Phase 1
-
Nitrous Oxide Neuroimaging
RECRUITING · Early Phase 1
-
Ketamine and Propofol NeuroImaging
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.